Pfizer Inc. Stock
€47.08
Your prediction
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Pfizer Inc. | 0.560% | -3.821% | -11.073% | 18.712% | -8.106% | 51.375% | 75.854% |
Eli Lilly Corp. | 0.020% | -2.194% | -11.396% | 29.813% | 18.390% | 187.409% | 324.099% |
Merck & Co. Inc. | 0.580% | 1.651% | -8.200% | 34.603% | 26.653% | 12.680% | 62.213% |
AbbVie Inc. | 1.470% | 1.504% | -9.778% | 42.137% | 15.642% | 133.322% | 130.355% |
Comments
News

Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR)

Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology
Pfizer Inc. (NYSE: PFE) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the companies have entered into a definitive agreement under which Pfizer will acquire GBT, a

PFIZER REPORTS SECOND-QUARTER 2022 RESULTS
Pfizer Inc. (NYSE: PFE) reported strong financial results for second-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer reaffirmed its previous 2022 revenue guidance